Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ARO-ALK7

NCT06937203

Arrowhead · Phase 1/2 · Recruiting · Enrollment 150

NCT06937203

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1 and Part 2 (optional cohort): ARO-ALK7n/rn/rn/rn/r
Part 1 and Part 2 (optional cohort): Placebon/rn/rn/rn/r
Part:2: ARO-ALK7 + Tirzepatiden/rn/rn/rn/r
Part 2: Placebo + Tirzepatiden/rn/rn/rn/r

Not shown

  • Part 1 and Part 2 (optional cohort): ARO-ALK7: endpoint not reported
  • Part 1 and Part 2 (optional cohort): Placebo: endpoint not reported
  • Part:2: ARO-ALK7 + Tirzepatide: endpoint not reported
  • Part 2: Placebo + Tirzepatide: endpoint not reported